Management of Stuttering Priapism

Diagnosis and Assessment

• A complete blood count, reticulocyte count, hemoglobin electrophoresis, and careful history of medications and substances that may precipitate episodes are recommended for the workup of stuttering priapism, followed by management focused on prevention of future episodes through hormonal therapy or self-injection of sympathomimetics, according to the American Urological Association 1
• Patients with stuttering priapism should be assessed for history of hematologic disorders, especially sickle cell disease, and evaluated for signs of trauma or malignancy in abdomen, pelvis, and perineum 1
• Diagnostic criteria for priapism include blood gas values of PO2 ≤30 mmHg, PCO2 ≥60 mmHg, and pH <7.25, indicating hypoxia, hypercapnia, and acidosis, and diagnosis involves determining the type of priapism by obtaining a history of duration of erection, presence and degree of pain, and previous episodes of priapism, as well as physical examination and corporal blood gas analysis to differentiate ischemic from non-ischemic priapism 2, 1
• Consider deep-seated infections that may not be immediately apparent, as suggested by the American College of Critical Care Medicine, to ensure proper diagnosis and treatment 3

Treatment

• GnRH agonists or antiandrogens are recommended for adult patients with stuttering priapism, according to the American Urological Association, while baclofen has shown success in case reports for the prevention of stuttering priapism, and terbutaline has limited evidence for prevention of stuttering priapism 1
• First-line treatment for priapism is intracavernosal phenylephrine (preferred sympathomimetic agent) diluted with normal saline to 100-500 μg/mL, administered in 1 mL injections every 3-5 minutes for up to 1 hour, with a success rate of 65-81%, as recommended by the American Urological Association 2, 1
• Treatment options and resolution rates are as follows:

2, 1

• Aspiration with or without irrigation is recommended if phenylephrine alone is unsuccessful, and surgical intervention (distal shunting) if pharmacologic measures fail 2, 1
• In patients with sickle cell disease, standard urologic management should not be delayed for disease-specific interventions, and systemic treatments alone have poor resolution rates (0-37%), with the American Urological Association suggesting managing priapism first while concurrently addressing sickle cell crisis 4, 1

Patient Education and Monitoring

• Patient education should include proper injection technique, appropriate dosing, recognition of systemic side effects, and when to seek emergency care for patients with stuttering priapism, with patients taking hydroxyzine informed about the rare but serious side effect of priapism, and early recognition and reporting of prolonged erections (>4 hours) is critical 2, 1
• Blood pressure and heart rate monitoring is essential during treatment with sympathomimetics, and patients should be observed for symptoms like hypertension, headache, bradycardia, tachycardia, and cardiac arrhythmias, with ECG monitoring recommended in patients with cardiovascular risk factors 1, 2
• Time is critical for ischemic priapism, with treatment efficacy decreasing after 48 hours, and significant risk of erectile dysfunction after 18 hours, and permanent erectile dysfunction likely after 36 hours, with follow-up essential to assess erectile function recovery, counsel regarding potential need for erectile dysfunction treatments, and evaluate for underlying causes such as medications, hematologic disorders, and malignancies 2, 1